• Firm commitments received for two-tranche placement to raise A$2.25 million
• Proceeds to be used for brand expansion, value-accretive opportunities, debt retirement, and working capital
• Placement shares to be issued at $0.0046 per share, an 8% discount to 5-day VWAP

Anagenics Limited (ASX:AN1) has received firm commitments to raise A$2.25 million before costs through a two-tranche placement of approximately 489,130,435 new shares to institutional and sophisticated investors at an issue price of $0.0046 per share. The issue price represents an 8% discount to the 5-day Volume Weighted Average Price (VWAP) up to and including Friday 5 December 2025. The first tranche of $342,461 will be issued within the company's existing placement capacity, while the second tranche of $1,907,539 is subject to shareholder approval at an EGM in early 2026. Proceeds from the placement will be used to expand existing brands, pursue complementary value-accretive business opportunities, retire debt, cover working capital requirements, and fund the costs of the placement. Participating AFSL holders will be entitled to a 6% + GST selling fee and, subject to shareholder approval, the grant of 122,282,609 alignment options with an exercise price of $0.008 and a 3-year expiry.